Amicus Therapeutics - New Analysis of Pombiliti + Opfolda Published in Muscle and Nerve

Published: 2025-06-04 06:38:17 ET FOLD

Published on 06/04/2025 at 06:38

PRINCETON - Amicus Therapeutics (Nasdaq: FOLD), announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD) in Muscle and Nerve.

In this new publication, based on a within group effect-size analysis, subjects who switched from alglucosidase alfa to cipa+mig achieved improvements or stability in most of the outcomes measured.

In PROPEL, 77% of patients (n=95) received enzyme replacement therapy (ERT) with alglucosidase alfa before study entry, with a median ERT duration of 7.4 years. In this new publication of post-hoc analysis from PROPEL, ERT-experienced patients switched to cipa+mig (n=65), showed improvement (d=0.2) or stability (--0.2